Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522730 | 1.00 | CNR1 (0.44) | CNR1CNR2PDE4BPDE4APDE4C | |
| SCHEMBL27472150 | 0.93 | HTT (0.41) | CNR1CNR2PDE4BPDE4APDE4C | |
| SCHEMBL1133458 | 0.84 | PSMB5 (0.46) | ESR2HTTALDH1A1TSHRACHE | |
| Lithium SCHEMBL30636805 | 0.82 | PSMB5 (0.44) | ESR2HTTALDH1A1TSHRACHE | |
| Hydrogen Sulfide SCHEMBL21381346 | 0.82 | PSMB5 (0.44) | ESR2HTTALDH1A1TSHRACHE | |
| SCHEMBL17180546 | 0.80 | PSMB5 (0.47) | ESR2ALDH1A1TSHRMAPK1ACHE | |
| SCHEMBL28860307 | 0.80 | HTT (0.47) | CNR1CNR2PDE4BPDE4APDE4C | |
| SCHEMBL28696280 | 0.80 | ALDH1A1 (0.45) | CNR1CNR2PDE4BPDE4APDE4C | |
| SCHEMBL851649 | 0.79 | SELL (0.55) | ESR2ALDH1A1TSHRMAPK1ALOX15 | |
| SCHEMBL29455292 | 0.79 | SELL (0.55) | ESR2ALDH1A1TSHRMAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503480-B2 | Cyclic phosphazene compound having oxaphosphorin ring-containing structure | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2025-12-23 | — | — | US | disclosed |
| US-20230339994-A1 | CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4202013-A1 | CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE | Fushimi Pharmaceutical Co., Ltd. (JP) | 2023-06-28 | — | — | EP | disclosed |
| CN-116194552-A | Cyclic phosphazene compounds having oxaphosphaphenanthrene-containing ring structure | 株式会社伏见制药所 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022019021-A1 | CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE | 株式会社伏見製薬所 | 2022-01-27 | — | — | WO | disclosed |
| US-7615650-B2 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20070179304-A1 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1710239-A1 | PROCESS FOR PRODUCING CHROMAN COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339994-A1 | CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE | PFAS, PHOSPHO1, PAF1 | CNR1 1599/4885CNR2 2538/4885PDE4B 1988/4885 |
| US-12503480-B2 | Cyclic phosphazene compound having oxaphosphorin ring-containing structure | PFAS, PHOSPHO1, PAF1 | CNR1 1599/4885CNR2 2538/4885PDE4B 1988/4885 |
| US-20070179304-A1 | Process for producing chroman compound | TAF9, TAF1, CHD1 | CNR1 1612/4885CNR2 2477/4885PDE4B 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.